Last 661.30
Change Today -19.30 / -2.84%
Volume 122.7K
CFBI On Other Exchanges
Symbol
Exchange
Tel Aviv
OTC US
NYSE Amex
As of 9:24 AM 02/1/15 All times are local (Market data is delayed by at least 15 minutes).

can fite biopharma ltd (CFBI) Snapshot

Open
$650.00
Previous Close
$680.60
Day High
$666.00
Day Low
$642.10
52 Week High
02/26/14 - $1,075
52 Week Low
11/18/14 - $445.50
Market Cap
141.0M
Average Volume 10 Days
126.7K
EPS TTM
$-2.64
Shares Outstanding
21.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CAN FITE BIOPHARMA LTD (CFBI)

can fite biopharma ltd (CFBI) Related Bloomberg News

View More Bloomberg News

can fite biopharma ltd (CFBI) Related Businessweek News

No Related Businessweek News Found

can fite biopharma ltd (CFBI) Details

Can-Fite BioPharma, Ltd., a clinical-stage biotechnology company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis, as well as completed Phase II study for the treatment of rheumatoid arthritis; completed Phase III study for the treatment of dry eye; completed Phase II study for the treatment of glaucoma; and initiating a Phase II study of CF101 for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of liver cancer; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company is headquartered in Petah-Tikva, Israel.

9 Employees
Last Reported Date: 04/24/14

can fite biopharma ltd (CFBI) Top Compensated Officers

Scientific Founder, Chief Executive Officer a...
Total Annual Compensation: 1.1M
Chief Operating & Financial Officer and Princ...
Total Annual Compensation: 782.0K
Vice President of Business Development
Total Annual Compensation: 736.0K
Compensation as of Fiscal Year 2013.

can fite biopharma ltd (CFBI) Key Developments

Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies

Can-Fite BioPharma Ltd. reported it has received positive data regarding its CF602 drug candidate in preclinical studies conducted by a third party. CF602 was tested in an experimental animal model of diabetic rats, which similar to diabetic patients, suffer from sexual dysfunction. Erectile dysfunction was assessed by monitoring the ratio between intra-cavernosal pressure (ICP) and mean arterial pressure (MAP) as a physiological index of erectile function. The ICP/MAP for the CF602 treated group improved by 118% over the placebo group. This data is similar to that achieved earlier by sildenafil (Viagra) in preclinical studies. In addition, treatment with CF602 reversed smooth muscle and endothelial damage, in a dose dependent manner, leading to the improvement in erectile dysfunction. CF602 is a novel A3 adenosine receptor allosteric modulator, enhancing the affinity of the natural ligand adenosine to its A3 adenosine receptor. Based on positive results from this preclinical study, the Company recently announced its plans to initiate a pre-clinical development program for CF602 in order to file an investigational new drug application (IND) with the U.S. Food and Drug Administration to allow human Phase I studies for the indication of sexual dysfunction.

Can-Fite Biopharma Ltd. Approves to Elect Israel Shamay as an External Director

On December 31, 2014, a Special General Meeting of Shareholders of Can-Fite BioPharma Ltd. approved a proposal to elect Israel Shamay as an external director for a three-year term.

Can-Fite BioPharma Ltd Completes Design of the Rheumatoid Arthritis Phase III Study of its Lead Drug Candidate CF101

Can-Fite BioPharma Ltd. announced that it completed the design of the Rheumatoid Arthritis (RA) Phase III study of its lead drug candidate CF101. Dr. M. Silverman, Can-Fite Medical Director, and Dr. Lee Simon, a key opinion leader in the field of autoimmune inflammatory diseases, designed the Phase III clinical study. The Phase III study will be a multicenter, randomized, double-blind, placebo-controlled, parallel-group study that will investigate the efficacy and safety of daily CF101 administered orally as a monotherapy for 12 weeks to patients with active RA. The study will have three arms, a 2 mg CF101 dose, a 3mg CF101 dose and placebo, given orally twice daily in the form of tablets. Approximately 300 patients are expected to be enrolled in the study, where sample size for each treatment group will be approximately 100 patients and will provide a statistical power of at least 90%. The study primary end point will be ACR 20 response at Week 12. The A3 adenosine receptor biomarker will be evaluated prior to treatment and its correlation to patients' response to the drug will be analyzed upon study conclusion. The Phase III design is based on positive data received from the company's completed Phase IIb study in which CF101 was administered as a monotherapy. The Phase IIb study was a 12-week multicenter, randomized, double-blind, placebo-controlled, parallel-group study involving 79 patients with active RA. In the study, patients treated with 1mg CF101 met all primary efficacy endpoints with statistically significant superiority over placebo in reducing signs and symptoms of RA as compared to the placebo.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CFBI:IT 661.30 -19.30

CFBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CFBI.
View Industry Companies
 

Industry Analysis

CFBI

Industry Average

Valuation CFBI Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAN FITE BIOPHARMA LTD, please visit www.canfite.co.il. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.